Skip to main content
. 2020 May 21;7(6):ofaa184. doi: 10.1093/ofid/ofaa184

Table 3.

Primary and Secondary Outcomes

Outcome Period 1 (n = 371) Period 2 (n = 87) Period 3 (n = 121) P Value
Complete bundle adherence,a No. (%) 241 (65) 47 (54) 92 (76) .004
Repeat blood cultures, No. (%) 291 (78) 66 (76) 105 (87) .09
Echocardiography, No. (%) 339 (91) 72 (83) 121 (100) <.0001
Removal of indwelling lines or nonapplicable, No. (%) 357 (96) 81 (93) 117 (97) .4
Appropriate antimicrobial therapy, No. (%) 354 (95) 83 (95) 120 (99) .1
Appropriate antimicrobial duration, No. (%) 324 (87) 76 (87) 112 (93) .3
Source control, No. (%) 126 (34) 39 (45) 54 (45) .04
Time to IDC, mean ± SD, d 1.06 ± 1.42 0.99 ± 0.85 0.83 ± 0.69 .2
Time to definitive therapy if change in therapy required, mean ± SD, d 2.49 ± 1.58 2.41 ± 1.35 2.77 ± 5.67 .7
Time to blood culture clearance, mean ± SD, h 52.6 ± 44.0 54.2 ± 63.3 41.9 ± 25.8 .06
Hospital LOS, mean ± SD, d 10.5 ± 6.96 8.85 ± 6.17 12.0 ± 10.7 .01
ICU LOS, mean ± SD, d 5.34 ± 6.10 5.33 ± 5.72 6.34 ± 6.28 .6
In-hospital all-cause mortality, No. (%) 16 (4.3) 2 (2.3) 6 (5.0) .6
30-d SAB-related readmission, No. (%) 10 (2.7) 0 (0) 0 (0) .07

Abbreviations: ICU, intensive care unit; IDC, infectious diseases consult; LOS, length of stay; SAB, Staphylococcus aureus bacteremia.

aPrimary end point.